Intellia Therapeutics and ReCode Therapeutics Join Forces to Develop Cystic Fibrosis Treatments

Intellia Therapeutics and ReCode Therapeutics are teaming up to develop new treatments for cystic fibrosis. Intellia's CRISPR-based gene editing platform will be combined with ReCode's delivery technology to target CFTR gene mutations. Initial efforts will focus on patients with limited treatment options, with potential for broader collaboration later. ReCode will lead preclinical and clinical development and global commercialization, while Intellia may lead U.S. commercialization for certain programs.